The increase in SG&A expenses included the impact of the following:
- Provision for the legal settlement of the TKT class action shareholder suit of $27 million (5% of product sales);
- An increase in the ADHD sales force to promote VYVANSE;
- The cost of the new GI sales force in the US; and
- The launches of DYNEPO, LIALDA and VYVANSE.
As a percentage of product sales, SG&A expenses were 53% (2006: 56%). For the three months to September 30, 2007 SG&A included a charge of $7.5 million for share based compensation (2006: $6.9 million), representing 1% of product sales (2006: 2%).
Depreciation and amortization
The depreciation charge for the three months to September 30, 2007 was $15.2 million (2006: $11.0 million). The increase in depreciation follows investment in Shire's infrastructure to support the continuing growth of the Company.
The amortization charge for the three months to September 30, 2007 was $31.1 million (2006: $14.6 million). The increase in amortization is primarily due to the amortization of DAYTRANA, DYNEPO and VYVANSE intangibles following the product launches in June 2006, March 2007 and July 2007 respectively.
Gain on disposal of product rights
For the three months to September 30, 2007 Shire recognized a gain of $7.1 million on the disposal of EQUETRO, a non-core product, to Validus. During the three months to September 30, 2006 Shire recognized a gain of $63.0 million on the disposal of ADDERALL to Duramed.
For the three months to September 30, 2007 Shire received interest income of $8.0 million (2006: $12.6 million). Interest income primarily relates to interest received on cash balances. Interest income for the three months to September 30, 2007 was lower than for the three months ending September 30, 2006 due to lower average cash balances following the acquisition of New River.
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved